Diffuse large B‐cell lymphoma on the back of a patient with AIDS: Successful treatment by the CD20 monoclonal antibody rituximab [PDF]
, 2005 Constanze Voigtländer +5 more
openalex +1 more source
Effects of miRNA-15 and miRNA-16 expression replacement in chronic lymphocytic leukemia : implication for therapy [PDF]
, 2017 This work was supported by: Associazione Italiana Ricerca sul Cancro (AIRC) Grant 5 x mille n.9980, (to M.F., F.M. A. N., P.T. and M.N.) ; AIRC I.G. n. 14326 (to M.F.), n.10136 and 16722 (A.N.), n.15426 (to F.F.).
Baio, G. +26 more
core +1 more source
Arthritis &Rheumatology, EarlyView.Objective This study aimed to investigate the mechanisms of immune dysregulation in a pediatric patient with monogenic lupus driven by IKZF1 haploinsufficiency. Methods Peripheral immune cells from a patient with IKZF1 haploinsufficiency, patients with lupus with no currently known genetic mutations, and healthy controls were analyzed using single‐cell
Qi Zheng +6 more
wiley +1 more source
Arthritis &Rheumatology, Accepted Article.Objective Rituximab, a CD20+ B cell depletion therapy, is frequently used to treat systemic lupus erythematosus (SLE). However, variability in patient response highlights the need for a deeper understanding of the underlying immune cell dynamics of B cell depletion and repopulation.
Haerin Jang +9 more
wiley +1 more source
Early‐stage health technology assessment of a curative gene therapy for multiple sclerosis
British Journal of Clinical Pharmacology, EarlyView.Aims Multiple sclerosis (MS) is associated with significant early morbidity, reduced life expectancy and substantial healthcare and societal costs. The primary objective of this study is to assess the early cost‐effectiveness potential of a novel gene therapy, IMMUTOL, for MS compared with current high‐efficacy treatment sequences.
Attila Imre, Balázs Nagy, Rok Hren
wiley +1 more source
193. Engineering CD20-Specific Chimeric Receptor-Redirected T Cells with Inducible Co-Expression of a Caspase-9 Based Suicide Switch for Adoptive Immunotherapy of CD20 Positive Lymphoma [PDF]
, 2012 openalex +1 more source
British Journal of Clinical Pharmacology, EarlyView.Aims Ocrelizumab is a humanized anti‐CD20 monoclonal antibody used in multiple sclerosis. Since its commercialization, several cases of ocrelizumab‐induced colitis have been reported in the scientific literature. Methods To explore the potential association of ocrelizumab with colitis as an adverse drug reaction (ADR), we conducted a descriptive and ...
Audrey Fresse +3 more
wiley +1 more source
Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia [PDF]
, 2012 K. H. Bauer +6 more
openalex +1 more source
Nanomaterial‐based immune therapeutic strategies in neurodegenerative diseases
BMEMat, EarlyView.This review highlights the immunomodulatory potential of nanomaterials (NMs) in treating neurodegenerative diseases (NDs). It focuses on their roles in regulating innate and adaptive immune responses to maintain immune homeostasis. By providing insights into these mechanisms, the review lays the groundwork for innovative NMs therapeutic strategies to ...
Xinru Zhou +6 more
wiley +1 more source
Cd20-negative diffuse large b-cell lymphoma subtype: a look at texas cancer registry
Hematology Reports, 2020 Introduction CD20-negative diffuse large B-cell lymphoma (DLBCL) histologic subtypes are rare and aggressive lymphomas. As these lymphomas are rare, most epidemiology and survival information is derived from case reports and case series.
Kartik Anand +2 more
doaj